Mutations Position Table
MAPT R5 Mutations
Mutation | Pathogenicity | DNA Change | Expected RNA | Protein Consequence | Coding/Non-Coding | Genomic Region | Neuropathology | Biological Effect | Primary Papers |
---|---|---|---|---|---|---|---|---|
R5H |
FTD : Unclear Pathogenicity, AD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 1 | In one case, neuronal loss in the frontal and temporal lobes; tau deposits predominantly in glia, progressive supranuclear palsy-like straight tubules; accumulation of 4-repeat (4R), Sarkosyl-insoluble tau.
|
Promoted fibril formation in vitro, but not in a cell-based assay. Reduced microtubule assembly in vitro; increased microtubule binding in cells. |
Hayashi et al., 2002 |
R5L |
FTD : Uncertain Significance | Substitution | Substitution | Missense | Coding | Exon 1 | Aggregated insoluble tau in subcortical regions was predominantly 4-repeat (4R) tau with 0 or 1 amino terminal inserts (i.e. 0N4R or 1N4R). Insoluble tau in cortical regions also contained 1N3R tau. |
Mixed results regarding effects on microtubule dynamics and tau aggregation. Multiple cellular processes affected in a Drosophila model. |
Poorkaj et al., 2002 |
R5C |
FTD : Uncertain Significance, PDD : Not Classified | Substitution | Substitution | Missense | Coding | Exon 1 | Unknown, but MRI of two carriers showed frontal atrophy, with one also having temporal atrophy and the other microangiopathy. FDG-PET showed hypoperfusion in frontal and temporal lobes of one carrier. |
Unknown, but PHRED-scaled CADD score (20.4) predicted a damaging effect. |
Schulte et al., 2015 |
Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.